Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.48 |
| ▸ | DAO | P14920 | 4/20 | 0.40 |
| ▸ | DDO | Q99489 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.35 |
| ▸ | ALPI | P09923 | 1/20 | 0.35 |
| ▸ | ALPG | P10696 | 1/20 | 0.35 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL207531 | 0.84 | AHR (0.50) | AHRDAOCYP1A2CYP2A6KDM4E | |
| SCHEMBL700070 | 0.84 | TNKS2 (0.40) | AHRKDM4E | |
| SCHEMBL3059466 | 0.73 | GPR84 (0.44) | GPR84ALDH1A1TDP1 | |
| SCHEMBL207534 | 0.73 | AHR (0.48) | AHRCYP1A2CYP2A6KDM4EFLT3 | |
| SCHEMBL207188 | 0.73 | CYP1A2 (0.46) | DAODDOCYP1A2CYP2A6KDM4E | |
| SCHEMBL6959510 | 0.73 | TYR (0.48) | CYP1A2FLT3LMNATSHRHSD17B10 | |
| SCHEMBL206725 | 0.73 | AHR (0.48) | AHRDAOCYP1A2CYP2A6KDM4E | |
| SCHEMBL4693144 | 0.72 | MEN1 (0.31) | — | |
| SCHEMBL700186 | 0.72 | METAP2 (0.50) | ALDH1A1HSD17B10BACE1METAP2 | |
| SCHEMBL209219 | 0.71 | DAO (0.48) | DAOKDM4EGPR84ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3891152-A1 | TYROSINE KINASE INHIBITORS, COMPOSITIONS AND METHODS THERE OF | Betta Pharmaceuticals Co., Ltd (CN) | 2021-10-13 | — | — | EP | claimed |
| EP-3321262-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2021-01-13 | — | — | EP | claimed |
| CN-106349217-B | Serine/threonine kinase inhibitors | 阵列生物制药公司 | 2020-08-28 | — | — | CN | claimed |
| WO-2020114499-A1 | TYROSINE KINASE INHIBITORS, COMPOSITIONS AND METHODS THERE OF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2020-06-11 | — | — | WO | claimed |
| EP-3321262-A1 | SERINE/THREONINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2018-05-16 | — | — | EP | claimed |
| US-20180127393-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2018-05-10 | — | — | US | claimed |
| EP-2791120-B1 | 1,3,5 -TRIAZINE-2-AMINE DERIVATIVES, PREPARATION THEREOF AND DIAGNOSTIC AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2016-02-24 | — | — | EP | claimed |
| US-9259470-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-02-16 | — | — | US | claimed |
| US-9115121-B2 | 1,3,5-triazine-2-amine derivatives, preparation thereof and diagnostic and therapeutic use thereof | SANOFI (FR) | 2015-08-25 | — | — | US | claimed |
| US-9102669-B2 | Substituted piperidinyl-pyridazinyl derivatives useful as SCD 1 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-11 | — | — | US | claimed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | claimed |
| EP-1577302-A1 | NOVEL ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | claimed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | claimed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | claimed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | claimed |
| US-20040122063-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-24 | — | — | US | claimed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | claimed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | claimed |
| EP-1270557-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-01-02 | — | — | EP | claimed |
| US-6333339-B1 | CENTRAL SYSTEM DISORDERS, SCHIZOPHRENIA AND COGNITION ACTIVATORS | MERCK PATENT GELLSCHAFT MIT BESCHRANKTER (DE) | 2001-12-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | AHR 3277/4885DAO 560/4885DDO 198/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | AHR 3277/4885DAO 560/4885DDO 198/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | AHR 3277/4885DAO 560/4885DDO 198/4885 |
| US-20180127393-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K11, TTBK1 | AHR 4684/4885DAO 2160/4885DDO 1158/4885 |
| US-20040122063-A1 | Ethylenediamine derivatives | ECE1, F2, ECE2 | AHR 1893/4885DAO 435/4885DDO 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.